Gut Bacteria & Blood Pressure: New Research & Potential Treatments
Berlin/London – Emerging research suggests a significant link between gut bacteria and blood pressure regulation. Specifically, a bacterial metabolite called indole-3-acetic acid (IAA) appears to act as a brake on stress neurons in the brain. This discovery could pave the way for novel approaches to preventing hypertension.
The connection between gut bacteria and blood pressure control is a rapidly evolving field of study. Scientists have found that IAA, produced by gut bacteria from the amino acid tryptophan, influences the activity of neurons in the hypothalamus – a key region of the brain.
These neurons, known as hypocretin neurons, function as a central switching station in the brain. When IAA levels are low, these neurons tend to become overactive, leading to increased sympathetic nervous system activity. This overactivity can cause the heart muscle to stiffen, a condition known as diastolic dysfunction, and a major contributor to heart failure with preserved ejection fraction (HFpEF).
The research suggests that increasing IAA production – potentially through dietary changes, probiotics, or supplements – could be a promising strategy for preventing hypertension and heart failure. Notably, studies have shown significantly lower IAA levels in women with hypertension, indicating that the gut-brain-heart axis may play a particularly important role in female cardiovascular health.
The implications of these findings are far-reaching. IAA could potentially serve as a biomarker to identify individuals at high risk for heart failure, enabling earlier preventative measures. Researchers emphasize, however, that further studies are needed to validate these results in clinical settings and to fully elucidate the underlying mechanisms.
A recent study published in in Nature investigated the relationship between specific characteristics of the gut microbiome and 24-hour ambulatory blood pressure measurements. The study, involving participants, found that gut microbiome alpha diversity was negatively associated with diastolic blood pressure variability. Four microbial species were specifically linked to blood pressure traits: Streptococcus sp001556435 (associated with higher systolic blood pressure), Intestinimonas massiliensis and Dysosmobacter sp001916835 (associated with lower systolic blood pressure), and ER4 sp900317525 (associated with lower systolic blood pressure variability). These species were also linked to specific metabolic patterns.
The American Heart Association has also acknowledged the growing body of evidence linking the gut microbiome to hypertension. A science advisory released in highlights the potential for modifying the gut microbiome as a novel therapeutic opportunity for controlling hypertension. Preclinical studies have consistently demonstrated that alterations in the gut microbiome can affect blood pressure.
While the precise mechanisms are still being investigated, it’s becoming increasingly clear that the gut microbiome isn’t simply a passive bystander in cardiovascular health. The interplay between gut bacteria, metabolites like IAA, and the brain’s regulation of blood pressure represents a complex but potentially targetable pathway for preventing and managing hypertension. Further research is crucial to determine how best to harness the power of the gut microbiome to improve cardiovascular outcomes.
this is an evolving area of research, and more studies are needed to fully understand the complex relationship between the gut microbiome and blood pressure. Individuals should not make any changes to their diet or treatment plan without consulting with a healthcare professional.